High-dose vitamin C safety in rare blood cell disorders
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Hormones & metabolism clinical trials.
This study tests whether high doses of vitamin C are safe for people with pyruvate kinase deficiency or G6PD deficiency, two genetic conditions that affect how red blood cells work. Researchers want to see if vitamin C might help, but first they need to confirm it won't cause harm.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed genetic diagnosis of pyruvate kinase deficiency (PKD) or G6PD class A deficiency
- You are 18 years old or older
- You can take oral medications by mouth or through a feeding tube
- You are not pregnant and do not plan to become pregnant during the study
- You do not have a known allergy to vitamin C (ascorbic acid)
- You can provide written consent to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether high-dose vitamin C given through an IV can improve outcomes in people with severe pneumonia. It may help your body fight infection and reduce complications, but it also has several safety checks.
This study tests if a medicine called Glycerol Phenylbutyrate (RAVICTI) is safe and helpful for children and young adults with a specific type of PDH deficiency, a rare genetic condition affecting energy use. If you qualify, you may get a new treatment option.
This trial tests whether adding high-dose vitamin C (ascorbate) to a standard chemotherapy drug (azacitidine) helps people with higher-risk myelodysplastic syndrome (MDS). It is for those who have had little or no prior treatment for MDS.
This trial tests a special high-dose vitamin C infusion, given based on how your body processes it, for people with advanced solid tumors. It aims to see if this vitamin C therapy can be safely combined with your current or new chemotherapy to help control the cancer.
This trial tests if adding high-dose vitamin C (ascorbate) to a standard combination of azacitidine and venetoclax can help adults with acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy. It aims to see if this combination is safe and effective.
This trial tests whether high doses of vitamin C, given with standard chemotherapy, can help people with multiple myeloma or related plasma cell disorders who have already tried several treatments. It includes a stem cell transplant step, so you must have stored stem cells.
Hear when a new Pyruvate Kinase Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.